Early minocycline treatment prevents a decrease in striatal dopamine in an SIV model of HIV-associated neurological disease

Journal of Neuroimmune Pharmacology

Volumn 7, Issue 2, 2012, Pages 454-464

  Meulendyke, Kelly A ^a   Pletnikov, Mikhail V ^a   Engle, Elizabeth L ^a   Tarwater, Patrick M ^b   Graham, David R ^a   Zink, M Christine ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Texas Tech University Health Sciences Center El Paso   (United States)

Author keywords

Dopamine; HIV; Minocycline; Monoamine oxidase; Oxidative stress; SIV

Indexed keywords

3 NITROTYROSINE; 3,4 DIHYDROXYPHENYLACETIC ACID; AMINE OXIDASE (FLAVIN CONTAINING); DOPAMINE; DOPAMINE TRANSPORTER; MINOCYCLINE; NEUROTRANSMITTER; SYNAPTOPHYSIN; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER 2; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CATABOLISM; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIV ASSOCIATED NEUROLOGICAL DISEASE; HOMEOSTASIS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOHISTOCHEMISTRY; MACACA; NEUROLOGIC DISEASE; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRUS LOAD; WHITE MATTER; ANIMAL; DISEASE MODEL; DRUG EFFECT; HIV ASSOCIATED DEMENTIA; METABOLISM; WESTERN BLOTTING;

3,4-DIHYDROXYPHENYLACETIC ACID; AIDS DEMENTIA COMPLEX; ANIMALS; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; IMMUNOHISTOCHEMISTRY; MACACA; MINOCYCLINE; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME;

EID: 84866500589     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-011-9332-1     Document Type: Article

References (64)

1. Agrawal L, Louboutin JP, Marusich E, Reyes BA, Van Bockstaele EJ, Strayer DS (2010) Dopaminergic neurotoxicity of HIV-1 gp120: reactive oxygen species as signaling intermediates. Brain Res 1306:116-130. doi:10.1016/j.brainres.2009. 09.113
2. Aksenova MV, Silvers JM, Aksenov MY, Nath A, Ray PD, Mactutus CF, Booze RM (2006) HIV-1 Tat neurotoxicity in primary cultures of rat midbrain fetal neurons: changes in dopamine transporterbinding and immunoreactivity. Neurosci Lett 395(3):235-239. doi:10.1016/j.neulet.2005.10.095 (Pubitemid 43213152)
3. Ances BM, Ellis RJ (2007) Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol 27(1):86-92. doi:10.1055/s-2006-956759 (Pubitemid 46239043)
4. Antonenko YN, Rokitskaya TI, Cooper AJ, Krasnikov BF (2010) Minocycline chelates Ca2+, binds to membranes, and depolarizes mitochondria by formation of Ca2+-dependent ion channels. J Bioenerg Biomembr 42(2):151-163. doi:10.1007/s10863-010-9271-1
5. Ara J, Przedborski S, Naini AB, Jackson-Lewis V, Trifiletti RR, Horwitz J, Ischiropoulos H (1998) Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4- henyl-1,2,3,6- tetrahydropyridine (MPTP). Proc Natl Acad Sci U S A 95(13):7659-7663. doi:10.1073/pnas.95.13.7659 (Pubitemid 28293309)
6. Barber SA, Uhrlaub JL, DeWitt JB, Tarwater PM, Zink MC (2004) Dysregulation of mitogen-activated protein kinase signaling pathways in simian immunodeficiency virus encephalitis. Am J Pathol 164(2):355-362. doi:10.1016/S0002-9440(10)63125-2 (Pubitemid 38364651)
7. Barnum CJ, Tansey MG (2010) Modeling neuroinflammatory pathogenesis of Parkinson's disease. Prog Brain Res 184:113-132. doi:10.1016/S0079-6123(10) 84006-3
8. Berg D, Youdim MB, Riederer P (2004) Redox imbalance. Cell Tissue Res 318(1):201-213. doi:10.1007/s00441-004-0976-5 (Pubitemid 39362641)
9. Berger JR, Arendt G (2000) HIV dementia: the role of the basal ganglia and dopaminergic systems. J Psychopharmacol 14(3):214-221. doi:10.1177/ 026988110001400304
10. Berger JR, Kumar M, Kumar A, Fernandez JB, Levin B (1994) Cerebrospinal fluid dopamine in HIV-1 infection. AIDS 8 (1):67-71. doi:10.1097/00002030- 199401000-00010 (Pubitemid 24094090)
11. Campbell JH, Burdo TH, Autissier P, Bombardier JP, Westmoreland SV, Soulas C, Gonzalez RG, Ratai EM, Williams KC (2011) Minocycline inhibition of monocyte activation correlates with neuronal protection in SIV NeuroAIDS. PLoS One 6(4):e18688. doi:10.1371/journal.pone.0018688
12. Clements JE, Babas T, Mankowski JL, Suryanarayana K, Piatak M Jr, Tarwater PM, Lifson JD, Zink MC (2002) The central nervous system as a reservoir for simian immunodeficiency virus (SIV): steady-state levels of SIV DNA in brain from acute through asymptomatic infection. Infect Dis 186(7):905-913. doi:10.1086/343768
13. Clements JE, Li M, Gama L, Bullock B, Carruth LM, Mankowski JL, Zink MC (2005) The central nervous system is a viral reservoir in simian immunodeficiency virus-infected macaques on combined antiretroviral therapy: a model for human immunodeficiency virus patients on highly active antiretroviral therapy. J Neurovirol 11 (2):180-189. doi:10.1080/13550280590922829 (Pubitemid 40852425)
14. Clements JE, Mankowski JL, Gama L, Zink MC (2008) The accelerated simian immunodeficiency virus macaque model of human immunodeficiency virus-associated neurological disease: from mechanism to treatment. J Neurovirol 14(4):309-317. doi:10.1080/13550280802132832
15. Czub S, Koutsilieri E, Sopper S, Czub M, Stahl-Hennig C, Muller JG, Pedersen V, Gsell W, Heeney JL, Gerlach M, Gosztonyi G, Riederer P, ter Meulen V (2001) Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs. Acta Neuropathol 101(2):85-91. doi:10.1007/s004010000313 (Pubitemid 32124479)
16. Diguet E, Fernagut PO, Wei X, Du Y, Rouland R, Gross C, Bezard E, Tison F (2004) Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Eur J Neurosci 19(12):3266-3276. doi:10.1111/j.0953-816X.2004.03372.x (Pubitemid 38859544)
17. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DL, Luecke S, Phebus LA, Bymaster FP, Paul SM (2001) Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A 98(25):14669-14674. doi:10.1073/pnas.251341998 (Pubitemid 33121449)
18. Ferris MJ, Mactutus CF, Booze RM (2008) Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in Neuro- AIDS. Neurosci Biobehav Rev 32(5):883-909. doi:10.1016/j.neubiorev.2008.01.004
19. Follstaedt SC, Barber SA, Zink MC (2008) Mechanisms of minocycline-induced suppression of simian immunodeficiency virus encephalitis: inhibition of apoptosis signal-regulating kinase 1. J Neurovirol 14(5):376-388. doi:10.1080/13550280802199898 (Pubitemid 352762877)
20. Gelman BB (2007) The neuropathology of HIV. Handb Clin Neurol 85:301-317. doi:10.1016/S0072-9752(07)85018-4
21. Gelman BB, Spencer JA, Holzer CE 3rd, Soukup VM (2006) Abnormal striatal dopaminergic synapses in National NeuroAIDS Tissue Consortium subjects with HIV encephalitis. J Neuroimmune Pharmacol 1(4):410-420. doi:10.1007/s11481-006-9030- 6 (Pubitemid 44786674)
22. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, Hilton JF, Spitalny GM, MacArthur RB, Mitsumoto H, Neville HE, Boylan K,Mozaffar T, Belsh JM, Ravits J, Bedlack RS, Graves MC, McCluskey LF, Barohn RJ, Tandan R, Western ALS Study Group (2007) Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 6 (12):1045-1053. doi:10.1016/S1474-4422(07)70270-3 (Pubitemid 350116691)
23. Halliwell B (1992) Reactive oxygen species and the central nervous system. J Neurochem 59(5):1609-1623. doi:10.1111/j.1471-4159.1992.tb10990.x
24. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I (2011) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75 (23):2087-2096. doi:10.1212/WNL.0b013e318200d727
25. Huang CL, Huang NK, Shyue SK, Chern Y (2003) Hydrogen peroxide induces loss of dopamine transporter activity: a calciumdependent oxidative mechanism. J Neurochem 86(5):1247-1259. doi:10.1046/j.1471-4159.2003.01936.x
26. Itoh K, Mehraein P, Weis S (2000) Neuronal damage of the substantia nigra in HIV-1 infected brains. Acta Neuropathol 99(4):376-384. doi:10.1007/ s004010051139 (Pubitemid 30179576)
27. Jordan J, Fernandez-Gomez FJ, Ramos M, Ikuta I, Aguirre N, Galindo MF (2007) Minocycline and cytoprotection: shedding new light on a shadowy controversy. Curr Drug Deliv 4(3):225-231. doi:10.2174/156720107781023938 (Pubitemid 47025406)
28. Kaul M, Lipton SA (2006) Mechanisms of neuronal injury and death in HIV-1 associated dementia. Curr HIV Res 4(3):307-318. doi:10.2174/157016206777709384 (Pubitemid 44027720)
29. Kim HS, Suh YH (2009) Minocycline and neurodegenerative diseases. Behav Brain Res 196(2):168-179. doi:10.1016/j.bbr.2008.09.040
30. Koutsilieri E, Sopper S, Scheller C, ter Meulen V, Riederer P (2002) Parkinsonism in HIV dementia. J Neural Transm 109(5-6):767-775. doi:10.1007/s007020200063 (Pubitemid 34810772)
31. Kraus RL, Pasieczny R, Lariosa-Willingham K, Turner MS, Jiang A, Trauger JW (2005) Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radicalscavenging activity. J Neurochem 94(3):819-827. doi:10.1111/j.1471-4159.2005.03219.x (Pubitemid 41098513)
32. Kumar AM, Borodowsky I, Fernandez B, Gonzalez L, Kumar M (2007) Human immunodeficiency virus type 1 RNA Levels in different regions of human brain: quantification using real-time reverse transcriptase-polymerase chain reaction. J Neurovirol 13 (3):210-224. doi:10.1080/13550280701327038 (Pubitemid 47050647)
33. Kumar AM, Fernandez J, Singer EJ, Commins D, Waldrop-Valverde D, Ownby RL, Kumar M (2009) Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains. J Neurovirol 15:1-18. doi:10.1080/13550280902973952
34. Kumar AM, Ownby RL, Waldrop-Valverde D, Fernandez B, Kumar M (2011) Human immunodeficiency virus infection in the CNS and decreased dopamine availability: relationship with neuropsychological performance. J Neurovirol 17(1):26-40. doi:10.1007/s13365-010-0003-4
35. Mallajosyula JK, Kaur D, Chinta SJ, Rajagopalan S, Rane A, Nicholls DG, Di Monte DA, Macarthur H, Andersen JK (2008) MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology. PLoS One 3(2):e1616. doi:10.1371/journal.pone.0001616 (Pubitemid 351863345)
36. Mattson MP, Haughey NJ, Nath A (2005) Cell death in HIV dementia. Cell Death Differ 12(Suppl 1):893-904. doi:10.1038/sj.cdd.4401577 (Pubitemid 41030604)
37. McArthur JC, Brew BJ, Nath A (2005) Neurological complications of HIV infection. Lancet Neurol 4(9):543-555. doi:10.1016/S1474-4422(05)70165-4 (Pubitemid 41139976)
38. Nath A, Sacktor N (2006) Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system. Curr Opin Neurol 19(4):358-361. doi:10.1097/01.wco.0000236614.51592.ca
39. Nath A, Anderson C, Jones M, Maragos W, Booze R, Mactutus C, Bell J, Hauser KF, Mattson M(2000) Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. J Psychopharmacol 14(3):222-227. doi:10.1177/026988110001400305
40. Navia BA, Cho ES, Petito CK, Price RW (1986) The AIDS dementia complex: II. Neuropathology. Ann Neurol 19(6):525-535. doi:10.1002/ana.410190603
41. Nosheny RL, Bachis A, Aden SA, De Bernardi MA, Mocchetti I (2006) Intrastriatal administration of human immunodeficiency virus-1 glycoprotein 120 reduces glial cell-line derived neurotrophic factor levels and causes apoptosis in the substantia nigra. J Neurobiol 66(12):1311-1321. doi:10.1002/neu.20288 (Pubitemid 44713810)
42. Pacher P, Beckman JS, Liaudet L (2007) Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87(1):315-424. doi:10.1152/physrev.00029.2006 (Pubitemid 46217686)
43. Park SU, Ferrer JV, Javitch JA, Kuhn DM (2002) Peroxynitrite inactivates the human dopamine transporter by modification of cysteine 342: potential mechanism of neurotoxicity in dopamine neurons. J Neurosci 22(11):4399-4405 (Pubitemid 37465656)
44. Pletnikov MV, Rubin SA, Schwartz GJ, Carbone KM, Moran TH (2000) Effects of neonatal rat Borna disease virus (BDV) infection on the postnatal development of the brain monoaminergic systems. Brain Res Dev Brain Res 119(2):179-185. doi:10.1016/S0165-3806(99)00168-6 (Pubitemid 30089808)
45. Ratai EM, Bombardier JP, Joo CG, Annamalai L, Burdo TH, Campbell J, Fell R, Hakimelahi R, He J, Autissier P, Lentz MR, Halpern EF, Masliah E, Williams KC, Westmoreland SV, Gonzalez RG (2010) Proton magnetic resonance spectroscopy reveals neuroprotection by oral minocycline in a nonhuman primate model of accelerated NeuroAIDS. PLoS One 5(5):e10523. doi:10.1371/journal.pone.0010523
46. Rumbaugh JA, Nath A (2006) Developments in HIV neuropathogenesis. Curr Pharm Des 12(9):1023-1044. doi:10.2174/138161206776055877
47. Sacktor N, Miyahara S, Deng L, Evans S, Schifitto G, Cohen BA, Paul R, Robertson K, Jarocki B, Scarsi K, Coombs RW, Zink MC, Nath A, Smith E, Ellis RJ, Singer E, Weihe J, McCarthy S, Hosey L, Clifford DB (2011) Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology 77(12):1135-1142. doi:10.1212/WNL.0b013e31822f0412
48. Sardar AM, Czudek C, Reynolds GP (1996) Dopamine deficits in the brain: the neurochemical basis of parkinsonian symptoms in AIDS. Neuroreport 7(4):910-912. doi:10.1097/00001756-199603220-00015 (Pubitemid 26167975)
49. Scheller C, Sopper S, Jenuwein M, Neuen-Jacob E, Tatschner T, Grunblatt E, ter Meulen V, Riederer P, Koutsilieri E (2005) Early impairment in dopaminergic neurotransmission in brains of SIVinfected rhesus monkeys due to microglia activation. J Neurochem 95(2):377-387. doi:10.1111/j.1471-4159.2005. 03373.x (Pubitemid 41457506)
50. Scheller C, Arendt G, Nolting T, Antke C, Sopper S, Maschke M, Obermann M, Angerer A, Husstedt IW, Meisner F, Neuen-Jacob E, Muller HW, Carey P, Ter Meulen V, Riederer P, Koutsilieri E (2010) Increased dopaminergic neurotransmission in therapynaive asymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses. J Neural Transm 117 (6):699-705. doi:10.1007/s00702-010-0415-6
51. Schildknecht S, Pape R, Muller N, Robotta M, Marquardt A, Burkle A, Drescher M, Leist M (2011) Neuroprotection by minocycline caused by direct and specific scavenging of peroxynitrite. J Biol Chem 286(7):4991-5002. doi:10.1074/jbc.M110.169565
52. Silvers JM, Aksenov MY, Aksenova MV, Beckley J, Olton P, Mactutus CF, Booze RM (2006) Dopaminergic marker proteins in the substantia nigra of human immunodeficiency virus type 1- infected brains. J Neurovirol 12(2):140-145. doi:10.1080/13550280600724319 (Pubitemid 44574604)
53. Steiner J, Haughey N, Li W, Venkatesan A, Anderson C, Reid R, Malpica T, Pocernich C, Butterfield DA, Nath A (2006) Oxidative stress and therapeutic approaches in HIV dementia. Antioxid Redox Signal 8(11-12):2089-2100. doi:10.1089/ars.2006.8.2089 (Pubitemid 46489633)
54. Tepper JM, Tecuapetla F, Koos T, Ibanez-Sandoval O (2010) Heterogeneity and diversity of striatal GABAergic interneurons. Front Neuroanat 4:150. doi:10.3389/fnana.2010.00150
55. Theodore S, Stolberg S, Cass WA, Maragos WF (2006) Human immunodeficiency virus-1 protein tat and methamphetamine interactions. Ann N Y Acad Sci 1074:178-190. doi:10.1196/annals.1369.018 (Pubitemid 44532823)
56. UNAIDS (2010) Global report: UNAIDS report on the global AIDS epidemic 2010. Joint United Nations Programme on HIV/AIDS (UNAIDS). http://www.unaids. org/documents/20101123-GlobalReport-em.pdf. Accessed July 25, 2011
57. Unal B, Ibanez-Sandoval O, Shah F, Abercrombie ED, Tepper JM (2011) Distribution of tyrosine hydroxylase-expressing interneurons with respect to anatomical organization of the neostriatum. Front Syst Neurosci 5:41. doi:10.3389/fnsys.2011.00041
58. Wallace DR, Dodson S, Nath A, Booze RM (2006) Estrogen attenuates gp120- and tat1-72-induced oxidative stress and prevents loss of dopamine transporter function. Synapse 59(1):51-60. doi:10.1002/syn.20214 (Pubitemid 41706154)
59. Williams KC, Hickey WF (2002) Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS. Annu Rev Neurosci 25:537-562. doi:10.1146/annurev.neuro25.112701.142822 (Pubitemid 34748028)
60. Witwer KW, Gama L, Li M, Bartizal CM, Queen SE, Varrone JJ, Brice AK, Graham DR, Tarwater PM, Mankowski JL, Zink MC, Clements JE (2009) Coordinated regulation of SIV replication and immune responses in the CNS. PLoS One 4(12):e8129. doi:10.1371/journal.pone.0008129
61. Zauli G, Secchiero P, Rodella L, Gibellini D, Mirandola P, Mazzoni M, Milani D, Dowd DR, Capitani S, Vitale M (2000) HIV-1 Tatmediated inhibition of the tyrosine hydroxylase gene expression in dopaminergic neuronal cells. J Biol Chem 275(6):4159-4165. doi:10.1074/jbc.275.6.4159 (Pubitemid 30094649)
62. Zink MC, Suryanarayana K, Mankowski JL, Shen A, Piatak M Jr, Spelman JP, Carter DL, Adams RJ, Lifson JD, Clements JE (1999) High viral load in the cerebrospinal fluid and brain correlates with severity of simian immunodeficiency virus encephalitis. J Virol 73(12):10480-10488
63. Zink MC, Coleman GD, Mankowski JL, Adams RJ, Tarwater PM, Fox K, Clements JE (2001) Increased macrophage chemoattractant protein-1 in cerebrospinal fluid precedes and predicts simian immunodeficiency virus encephalitis. J Infect Dis 184(8):1015-1021. doi:10.1086/323478 (Pubitemid 32955118)
64. Zink MC, Uhrlaub J, DeWitt J, Voelker T, Bullock B, Mankowski J, Tarwater P, Clements J, Barber S (2005) Neuroprotective and antihuman immunodeficiency virus activity of minocycline. JAMA 293(16):2003-2011. doi:10.1001/jama.293.16. 2003 (Pubitemid 40570894)